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Abstract
Introduction:  Human  papillomavirus  has  been  associated  with  head  and  neck  squamous  cell
carcinoma.  However,  there  is  no  conclusive  evidence  on  the  prevalence  of  oral  or  pharyngeal
infection by  human  papillomavirus  in  the  Brazilian  population.
Objective:  To  determine  the  rate  of  human  papillomavirus  infection  in  the  Brazilian  population.
Methods: Systematic  review  of  published  articles.  Medline,  The  Cochrane  Library,  Embase,
Lilacs (Latin  American  and  Caribbean  Health  Sciences)  and  Scielo  electronic  databases  were
searched. The  search  included  published  articles  up  to  December  2014  in  Portuguese,  Spanish
and English.  A  wide  search  strategy  was  employed  in  order  to  avoid  publication  biases  and  to
assess studies  dealing  only  with  oral  and/or  oropharyngeal  human  papillomavirus  infections  in
the Brazilian  population.
Results:  The  42  selected  articles  enrolled  4066  patients.  It  was  observed  that  oral  or  oropharyn-
geal human  papillomavirus  infections  were  identiﬁed  in  738  patients  (18.2%;  IC  95  17.6--18.8),
varying between  0.0%  and  91.9%.  The  prevalences  of  oral  or  oropharyngeal  human  papillo-
mavirus infections  were  respectively  6.2%,  44.6%,  44.4%,  27.4%,  38.5%  and  11.9%  for  healthy
people, those  with  benign  oral  lesions,  pre-malignant  lesions,  oral  or  oropharyngeal  squamous
cell carcinoma,  risk  groups  (patients  with  genital  human  papillomavirus  lesions  or  infected
partners) and  immunocompromised  patients.  The  risk  of  human  papillomavirus  infection  was
estimated  for  each  subgroup  and  it  was  evident  that,  when  compared  to  the  healthy  popu-
lation, the  risk  of  human  papillomavirus  infection  was  approximately  1.5--9.0  times  higher, Please cite this article as: de Matos LL, Miranda GA, Cernea CR. Prevalence of oral and oropharyngeal human papillomavirus infection in
razilian population studies: a systematic review. Braz J Otorhinolaryngol. 2015;81:554--67.
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especially  in  patients  with  an  immunodeﬁciency,  oral  lesions  and  squamous  cell  carcinoma.  The
rates of  the  most  well-known  oncogenic  types  (human  papillomavirus  16  and/or  18)  also  show
this increased  risk.
Conclusions:  Globally,  the  Brazilian  healthy  population  has  a  very  low  oral  human  papillomavirus
infection  rate.  Other  groups,  such  as  at-risk  patients  or  their  partners,  immunocompromised
patients,  people  with  oral  lesions  and  patients  with  oral  cavity  or  oropharyngeal  squamous  cell
carcinoma  have  a  high  risk  of  human  papillomavirus  infection.
© 2015  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Published  by
Elsevier Editora  Ltda.  All  rights  reserved.
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Prevalência  de  infecc¸ão  oral  e  orofaríngea  pelo  HPV  em  estudos  na  populac¸ão
brasileira:  revisão  sistemática
Resumo
Introduc¸ão: O  papilomavírus  humano  (HPV)  tem  sido  associado  ao  carcinoma  de  células
escamosas (CCE)  de  cabec¸a  e  pescoc¸o.  No  entanto,  não  existem  evidências  conclusivas  sobre  a
prevalência  de  infecc¸ão  oral  ou  faríngea  pelo  HPV  na  populac¸ão  brasileira.
Objetivo:  Determinar  a  taxa  de  infecc¸ão  pelo  HPV  na  populac¸ão  brasileira.
Método: Revisão  sistemática  de  artigos  publicados.  Foram  feitas  buscas  nos  seguintes  ban-
cos de  dados  eletrônicos:  Medline,  The  Cochrane  Library,  Embase,  Lilacs  (Latin  American  and
Caribbean  Health  Sciences)  e  Scielo.  A  busca  considerou  artigos  publicados  até  dezembro  de
2014, em  português,  espanhol  e  inglês.  Foi  utilizada  uma  ampla  estratégia  de  busca  com  o  intu-
ito de  evitar  viés  de  publicac¸ão  e  também  para  que  fossem  avaliados  estudos  que  tratassem
apenas de  infecc¸ões  orais  e/ou  orofaríngeas  pelo  HPV  na  populac¸ão  brasileira.
Resultados:  Os  42  artigos  selecionados  incluíram  4.066  pacientes.  Observou-se  que  infecc¸ões
orais ou  orofaríngeas  pelo  HPV  foram  identiﬁcadas  em  738  pacientes  (18,2%;  IC95  17,6-18,8),
variando entre  0,0-91,9%.  As  prevalências  de  infecc¸ões  orais  ou  orofaríngeas  pelo  HPV  foram,
respectivamente,  6,2%,  44,6%,  44,4%,  27,4%,  38,5%  e  11,9%  em  pacientes  saudáveis,  com
lesões orais  benignas,  com  lesões  pré-malignas,  com  CCE  oral  ou  orofaríngeo,  grupos  de  risco
(pacientes  com  lesões  genitais  pelo  HPV  ou  parceiros  infectados)  e  pacientes  imunodeﬁcientes.
O risco  de  infecc¸ão  pelo  HPV  foi  estimado  para  cada  subgrupo,  quando  ﬁcou  evidente  que,
em comparac¸ão  com  a  populac¸ão  saudável,  o  risco  de  infecc¸ão  por  HPV  foi  aproximadamente
1,5-9,0 vezes  mais  alto,  especialmente  em  pacientes  com  imunodeﬁciência,  lesões  orais  e  CCE.
Os percentuais  dos  tipos  oncogênicos  mais  conhecidos  (HPV  16  e/ou  18)  também  mostram  esse
aumento no  risco.
Conclusões:  A  populac¸ão  brasileira  saudável  apresenta  taxa  de  infecc¸ão  oral  pelo  HPV  muito
baixa. Outros  grupos,  por  exemplo,  pacientes  de  risco  ou  seus  parceiros,  pacientes  imunod-
eﬁcientes, indivíduos  portadores  de  lesões  orais  e  pacientes  com  CCE  de  cavidade  oral  ou
orofaringe apresentam  maior  risco  de  infecc¸ão  pelo  HPV.
© 2015  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Publicado  por
Elsevier Editora  Ltda.  Todos  os  direitos  reservados.
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Human  papillomavirus  (HPV)  is  one  of  the  most  common
causes  of  sexually  transmitted  infections.  HPV  is  classiﬁed
as  high-risk  (or  oncogenic),  which  is  associated  with  malig-
nancies,  or  low-risk  (or  non-oncogenic),  which  is  related  to
benign  diseases.1 The  relationship  between  HPV  infections,
especially  types  16  and  18,  and  anogenital  cancer  is  well
established.  In  the  last  decade,  relationships  between  HPV
and  head  and  neck  squamous  cell  carcinoma  (HNSCC)  have
been  established,  especially  in  younger  patients  without  the
classic  risk  factors  (tobacco  and  alcohol  abuse).2
s
i
rThe  incidence  of  HNSCC  is  increasing  worldwide,  includ-
ng  in  Brazil,  and  the  role  of  HPV  infection  in  its
arcinogenesis  might  explain  the  trend.3 A  previously  pub-
ished  meta-analysis  conducted  in  the  1990s  with  4680
amples  identiﬁed  an  HPV  infection  prevalence  of  10.0%  in
ormal  mucosa,  which  was  signiﬁcantly  less  than  for  leuko-
lakia  (22.2%)  and  oral  SCC  (46.5%).4 However,  there  is  no
onclusive  evidence  regarding  the  prevalence  of  oral  or  pha-
yngeal  HPV  infections  in  the  Brazilian  population.  Existing
tudies  resort  to  various  methods,  either  in  sampling  or
n  the  detection  of  HPV,  eventually  producing  discrepant
esults.5
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Therefore,  the  aim  of  the  present  study  was  to  determine
he  rate  of  HPV  infection  in  the  Brazilian  population  based
n  a  systematic  review  of  published  articles.
ethods
thics
he  present  study  was  not  submitted  to  IRB  because  it  was
 systematic  review  exclusively  with  published  articles.
earch  strategy  and  inclusion  criteria
wo  authors  performed  searches  of  MEDLINE,  The  Cochrane
ibrary,  Embase,  LILACS,  and  SciELO  electronic  databases.
he  search  included  published  articles  up  to  Decem-
er  of  2014  in  Portuguese,  Spanish,  and  English.  A  wide
earch  strategy  was  employed  in  order  to  avoid  publica-
ion  biases  and  to  assess  studies  dealing  only  with  oral
nd/or  oropharyngeal  HPV  infections  in  the  Brazilian  popula-
ion.  The  following  Medical  Subject  Headings  and  keywords
ere  used:  ‘‘human  papillomavirus’’  and  ‘‘Brazil’’  and
‘mouth’’  OR  ‘‘human  papillomavirus’’  and  ‘‘Brazil’’  and
‘oropharynx’’.  Reference  lists  of  previously  obtained  arti-
les  were  also  analyzed  manually  so  that  other  relevant
tudies  could  be  identiﬁed  for  inclusion  in  the  present  study.
xclusion  criteria
rticles  that  were  not  published  in  Portuguese,  Spanish,
r  English,  or  where  the  full  text  could  not  be  obtained,
ere  excluded  from  the  search.  Articles  that  had  no  data  or
nsufﬁcient  data  regarding  HPV  statuses  were  also  excluded.
rticles  from  the  same  institution  by  the  same  set  of
uthors  were  screened  for  study  time-period  overlaps,  and
f  repetitive  information  was  presented,  duplicated  data
ere  excluded  and  data  from  the  most  complete  data  set
ere  analyzed.  Other  exclusion  criteria  were:  articles  that
ncluded  only  patients  who  tested  positive  for  oral  or  orop-
aryngeal  HPV;  articles  based  on  a  pediatric  population,
nimals,  or  cell  lines;  review  articles,  case  reports,  or  case
eries  studies;  HPV  in  sites  other  than  the  mouth  and/or
ropharynx;  articles  that  did  not  study  HPV;  and  studies
ith  populations  other  than  Brazilians  or  multicentric  stud-
es  in  which  it  was  not  possible  to  separate  the  Brazilian
opulation’s  HPV  status.
ata  extraction
ll  data  were  extracted  by  two  independent  authors  using
 data  recording  form  developed  for  this  purpose,  which
ncluded  the  following:  city  and  state,  population  charac-
eristics,  dates  when  the  sample  was  obtained,  the  type  of
aterial  collected  (parafﬁn-embedded,  fresh  tissue,  and/or
rushing  mucosa)  and  subsite  (mouth  and/or  oropharynx),
ge,  smoking  status,  alcohol  intake,  gender,  technology
sed  for  HPV  detection  (polymerase  chain  reaction  [PCR],
n  situ  hybridization,  and/or  immunohistochemistry  [IHC]),
nd  general  and  speciﬁc  HPV  status  (HPV  16  and/or  HPV  18).
2
s
g
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ny  discrepancies  were  addressed  following  discussion  and
onsensus  between  the  two  authors.
ata  analysis
he  articles  were  initially  organized  in  the  following  groups
o  facilitate  the  analysis:  (1)  oral  or  oropharyngeal  HPV
nfection  in  healthy  patients;  (2)  oral  or  oropharyngeal  HPV
nfection  in  patients  with  benign  or  premalignant  lesions;
3)  HPV  infections  in  the  oral  cavity  and/or  oropharyngeal
quamous  cell  carcinoma  (SCC);  (4)  oral  or  oropharyngeal
PV  infection  where  patients  or  patients’  partners  had  gen-
tal  HPV  infections;  (5)  oral  or  oropharyngeal  HPV  infection
n  immunodeﬁcient  patients.
For  the  statistical  analysis,  the  HPV  status  data  were
ategorized  into  the  following  groups:  healthy  patients,
mmunodeﬁcient  patients,  high-risk  patients  (those  with
enital  HPV  infections  or  infected  partners),  patients
ith  benign  lesions,  with  premalignant  lesions  (dysplasia,
eukoplakia  or  erythroplakia),  and  with  squamous  cell  car-
inoma  (oral  cavity  or  oropharyngeal  SCC).  Microsoft  Excel
Microsoft  Corp® --  Redmond,  WA,  United  States)  was  used  to
abulate  data  and  to  perform  weighted  average,  frequency,
nd  95%  conﬁdence  interval  (95%  CI)  calculations.  SPSS® ver-
ion  17.0  (SPSS® Inc  --  Illinois,  United  States)  was  used  for
ogistic  regressions  to  assess  the  risk  of  HPV  infection  in  each
roup,  calculating  odds  ratios  (OR)  and  95%  CIs.  In  all  of
hese  analyses,  the  probability  of  making  an    or  type  I  error
as  considered  as  less  than  5%  (p  <  0.05).
esults
sing  the  established  search  strategy  and  inclusion  crite-
ia,  84  abstracts  were  identiﬁed  (Fig.  1).  Exclusion  criteria
ncluded:  studies  with  subsites  other  than  the  mouth  or
ropharynx  (13),  articles  without  HPV  studies  (seven),  stud-
es  of  pediatric  populations  (ﬁve),  casuistic  studies  (four),
nobtainable  data  (four),  non-human  samples  (three),  case
eports  or  series  of  cases  studies  (three),  review  articles
two),  and  studies  of  non-Brazilian  populations  (one).  Based
n  the  criteria,  42  articles5--46 were  included  in  the  sys-
ematic  review  (Table  1),  and  it  was  noted  that  the  great
ajority  of  the  studies  were  conducted  in  the  last  decade,
ith  oral  samples.
Brazil  is  a  large  country  with  a  population  of  approxi-
ately  200,000,000.  The  articles  analyzed  came  from  all
ver  the  country,  with  concentrations  in  state  capitals  and
ore  developed  regions  (for  example,  the  Southeast  Region,
hich  had  61.9%  of  the  studies,  especially  São  Paulo  State)
s  shown  in  Fig.  2.
emographic  data
ight  articles  (19%)  studied  oral  or  oropharyngeal  HPV  infec-
ion  in  healthy  patients,  two  (4.8%)  exclusively  analyzed  HPV
tatus  of  patients  with  benign  or  premalignant  oral  lesions,
2  (52.4%)  analyzed  SCC  patients  (comparative  or  population
tudies),  eight  (19%)  speciﬁcally  studied  oral  or  oropharyn-
eal  HPV  infections  in  patients  with  genital  HPV  infections
r  lesions  or  with  infected  partners,  and  two  (4.8%)
Oral  HPV  prevalence  in  Brazilian  population  studies  557
Abstracts selected: 84
First exclusion: 33 abstracts
• Other subsites that not OC/OP: 13
• Not HPV study: 7
• Only children population: 5
• Not human samples: 3
• Case reports or series of cases: 3
• Literature review: 2
Second exclusion:  9 studies
• Same casuistic: 4
• Impossibility to obtain data: 4
• Not a Brazilian population: 1
Abstracts selected for
complete evaluation of the
manuscript: 51
Articles included for
systematic review: 42
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5Figure  1  Flowcha
studied  immunodeﬁcient  patients  (Fanconi’s  anemia  and  HIV
patients).
Thirty-four  articles  (80.9%)  included  demographic  data,
which  are  displayed  in  Table  2.  It  was  observed  that  the
weighted  average  for  age  was  higher  in  the  SCC  group  (59
years  old)  than  the  others  (30--36  years  old).  Tobacco  use
and  alcohol  intake  were  similarly  higher  in  these  patients.
Oral/oropharyngeal  HPV  status
The  42  articles  included  4066  enrolled  patients.  It  was
observed  that  oral  or  oropharyngeal  HPV  infections  were
identiﬁed  in  738  patients  (18.2%;  95%  CI  17.6%--18.8%),  vary-
ing  between  0.0%  and  91.9%.  HPV  status  was  assessed  using
PCR  in  90.5%  of  the  studies  and  by  in  situ  hybridization  in
the  others.
General  HPV,  HPV  16,  HPV  18,  and  HPV  16/18  prevalences
are  displayed  in  Table  3.  It  was  observed  that  higher  rates
of  HPV  infection  occurred  in  patients  with  oral  lesions  and
in  people  in  high-risk  groups  (patients  with  genital  lesions
or  infected  partners).  It  was  also  noted  that  the  healthy
population  had  a  very  low  HPV  infection  rate  (6.2%;  95%  CI
5.7--6.7%).
The  risk  of  HPV  infection  was  estimated  for  each  sub-
group  (Table  4).  It  was  evident  that,  when  compared  to  the
healthy  population,  the  risk  of  HPV  infection  was  approxi-
mately  1.5-  to  9.0-fold  higher,  especially  in  patients  with  an
immunodeﬁciency,  oral  lesions,  and  SCC.  The  rates  of  the
most  well-known  oncogenic  types  (HPV  16  and/or  18)  also
show  this  increased  risk.
Discussion
This  studied  summarized,  for  the  ﬁrst  time,  the  prevalence
of  oral  and  oropharyngeal  infections  in  the  Brazilian  popu-
lation.  This  systematic  review  was  conducted  with  a  large
series  of  oral  and  oropharyngeal  HPV  statuses  in  different
populations,  and  data  were  stratiﬁed  into  groups  of  patients
in  order  to  acquire  clinically  relevant  information  toward
(
I
5
gf  article  selection.
he  management  of  each  speciﬁc  group.  However,  some
oints  require  discussion.
ral/oropharyngeal  HPV  infection
he  prevalence  of  oral  HPV  has  been  estimated  to  be  in  the
ange  2.4--7.5%  among  young  adults  in  the  United  States.47 A
ecent  study48 investigated  the  prevalence  of  oral  HPV  infec-
ions  in  the  general  US  population  (5579  men  and  women
ged  between  14  and  69  years)  in  2009  and  2010.  The  over-
ll  prevalence  of  oral  HPV  infections  for  any  HPV  type  was
.9%  (95%  CI  5.7%--8.3%),  the  prevalence  of  high-risk  HPV
ypes  was  3.7%  (95%  CI  3.0%--4.6%),  and  that  of  HPV  16  was
.0%  (95%  CI  0.7%--1.3%).  The  present  study  identiﬁed  a  rate
f  6.2%  for  any  HPV  infection  and  1.4%  for  HPV  16  infection
mong  2060  healthy  patients,  which  is  similar  to  large  series
round  the  world.
Considering  other  groups  analyzed  in  the  present  study,
ther  studies  also  identiﬁed  an  increased  prevalence  of  oral
PV  infection.  A  study  conducted  in  Zagreb,  Croatia,  estab-
ished  a  rate  of  17.7%  for  HPV  positivity  in  oral  lesions,
ith  a signiﬁcantly  higher  presence  in  benign  proliferative
ucosal  lesions  (18.6%).  High-risk  HPV  types  were  predom-
nantly  found  in  potentially  malignant  oral  disorders  (HPV
6  in  4.3%)  with  a  rate  for  any  HPV  infection  of  15.5%.49 A
eta-analysis  conducted  with  dysplasia  specimens  from  the
ral  cavity  and  oropharynx  identiﬁed  an  overall  prevalence
f  HPV  16/18  of  24.5%  (95%  CI  16.4%--36.7%).50 Another  study
dentiﬁed  a prevalence  of  6.9%  for  oral  HPV  infection  in  HIV
atients.51 Studies  of  this  relationship  in  other  immunodeﬁ-
ient  patients  are  scarce.  Oral  HPV  infections  were  found  in
lmost  10.2%  to  75%  of  patients  with  genital  HPV  lesions  or
nfected  partners  worldwide.52,53
Genomic  DNA  of  oncogenic  HPV,  especially  type  16,
as  been  detected  in  approximately  25%  of  HNSCC  cases
orldwide.54 In  a  large-scale  meta-analysis,  Kreimer  et  al.
5 reported  an  overall  HPV  prevalence  of  25.9%  in  HNSCC
23.5%  for  oral  cavity  SCC  and  35.6%  for  oropharyngeal  SCC).
n  a  recent  French  multi-institutional  study,  St  Guily  et  al.
6 reported  an  overall  prevalence  of  46.5%  for  oropharyn-
eal  SCC  and  10.5%  for  oral  cavity  SCC.  The  present  review
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Table  1  Demographic  data  of  populations  and  samples  collected  in  the  included  studies.
Article  Brazilian  city,  state  Population
characteristics
Sample  date  Collected  material  Subsite
Oral/oropharyngeal  HPV  infection  in  healthy  patients
Sacramento  (2006)6 São  José  do  Rio  Preto,  SP  50  healthy  patients  2006  Fresh  tissue  Oropharynx
Esquenazi (2010)7 Rio  de  Janeiro,  RJ  100  healthy  university
students
2006--2007  Brushing  Mouth
Horewicz (2010)8 Campinas,  SP  104  patients  with
gingival  disorders  and
healthy  mucosa
2006--2009  Parafﬁn-embedded
tissue
Mouth
Tristão (2012)9 Araras,  SP  125  healthy  patients  2007--2012  Brushing  Mouth
Kreimer (2013)10 São  Paulo,  SP  499  healthy  men  2007--2013  Brushing  Mouth
Cavenaghi (2013)5 Votuporanga,  SP  124  healthy  patients  2011  Brushing  Mouth  and
oropharynx
Araujo (2014)11 Belém,  PA  166  healthy  patients  2014  Brushing  Mouth  and
oropharynx
Machado (2014)12 Campo  Grande,  MS  514  healthy  men  2014  Brushing  Mouth
Oral/oropharyngeal  HPV  infection  in  patients  with  benign  or  premalignant  lesions
Betiol (2012)13 Araras,  SP  16  healthy  patients  and
8 cases  of  leukoplakia
2010--2012  Brushing  Mouth
Fonseca-Silva (2012)14 Montes  Claros,  MG  24  normal  mucosa
samples  and  48  oral
dysplasia  lesions
Institutional
archive
Parafﬁn-embedded
tissue
Mouth
HPV infection  in  oral  cavity  and/or  oropharyngeal  squamous  cell  carcinoma  patients
Comparative  studies  (healthy  people  versus  SCC  patients)
Cortezzi  (2004)15 São  José  do  Rio  Preto
and  São  Paulo,  SP
16  SCC  and  142  healthy
patients
2004  Fresh  tissue  (SCC)
Brushing  (healthy)
Mouth  and
oropharynx
Silva (2007)16 São  Paulo,  SP  50  SCC  and  10  healthy
volunteers
2007  Fresh  tissue  Mouth
Mazon (2011)17 Araraquara,  SP  18  benign  lesions,  18
premalignant  lesions,
and  19  SCC
Institutional
archive
Parafﬁn-embedded
tissue
Mouth
Comparative  studies  (benign  lesions  versus  SCC  patients)
Soares  (2002)18 Araraquara,  SP  20  cases  of  benign  oral
lesions  and  10  SCC
1992--1998  Parafﬁn-embedded
tissue
Mouth
Soares (2003)19 Araraquara,  SP  30  benign  lesions  and  27
SCC
Institutional
archive
Parafﬁn-embedded
tissue
Mouth
Fregonesi (2003)20 Araraquara,  SP  19  benign  lesions,  10
premalignant  lesions  and
17  SCC
Institutional
archive
Parafﬁn-embedded
tissue
Mouth
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Acay  (2008)21 São  Paulo,  SP 40  leukoplakia  and  10
SCC
Institutional
archive
Parafﬁn-embedded
tissue
Mouth
Lira (2010)22 Ribeirão  Preto-SP 16  non-malignant  oral
lesions  and  20  in  situ
SCC  and  50  SCC
2009  Parafﬁn-embedded
tissue
Mouth
Fregonezi (2012)23 Ribeirão  Preto,  SP 19  benign  oral  lesions,
16  premalignant  oral
lesions  and  17  SCC
1992--2005 Parafﬁn-embedded
tissue
Populational  studies
Miguel  (1998)24 São  Paulo,  SP 28  SCC 1995--1996 Fresh  tissue Mouth  and
oropharynx
Soares (2007)25 Natal,  RN 75  SCC 2000--2003 Parafﬁn-embedded
tissue
Mouth
Oliveira (2008)26 Ribeirão  Preto,  SP 87  SCC Institutional
archive
Parafﬁn-embedded
tissue
Mouth
Simonato  (2008)27 Arac¸atuba,  SP  29  SCC  1991--2005  Parafﬁn-embedded
tissue
Mouth
Soares (2008)28 Natal,  RN  33  SCC  1996--2004  Parafﬁn-embedded
tissue
Mouth
Oliveira (2009)29 Natal,  RN 88  SCC 1996--2004 Parafﬁn-embedded
tissue
Mouth
Pereira (2011)30 Natal,  RN 27  SCC Institutional
archive
Parafﬁn-embedded
tissue
Mouth
Spindula-Filho  (2011)31 Goiânia,  GO 39  SCC  and  8  verrucous
carcinoma
2010  Parafﬁn-embedded
tissue
Mouth
Cordeiro-Silva (2012)32 Vitória,  ES  and  Goiânia,
GO
45  SCC 2012  Parafﬁn  and  fresh
tissue
Mouth  and
oropharynx
Kaminagakura (2012)33 São  Paulo,  SP 114  SCC 1970--2006 Parafﬁn-embedded
tissue
Mouth
Marques-Silva  (2012)34 Montes  Claros,  MG 40  SCC 1996--2007 Parafﬁn-embedded
tissue
Mouth  and
oropharynx
Cantarutti (2014)35 Brasilia,  DF 26  SCC 2005--2011 Parafﬁn-embedded
tissue
Mouth  and
oropharynx
Lopez (2014)36 Goiânia,  GO;  Rio  de
Janeiro,  RJ;  São  Paulo,
SP;  Ribeirão  Preto,  SP
222  SCC 1998--2008 Parafﬁn-embedded
and  fresh  tissue
Mouth  and
oropharynx
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Table  1  (Continuación  )
Article  Brazilian  city,  state  Population
characteristics
Sample  date  Collected  material  Subsite
Oral/oropharyngeal  HPV  infection  in  patients  with  genital  HPV  infection
Comparative  studies  (healthy  people  versus  patients  with  genital  HPV  infection)
Gonc¸alves (2006)37 Campinas,  SP  70  women  with  genital
HPV  infection  and  70
healthy  women
2001--2002  Saliva  Mouth
Marques (2013)38 Brasilia,  DF  43  women  with  NIC
lesions  and  21  partners
2011  Brushing  Mouth  and
oropharynx
Ribeiro (2014)39 Recife,  PE  31  married  couples:  men
with  penis  squamous  cell
carcinoma  or  precursor
lesions  and  their
partners
2006--2007  Brushing  Mouth
Vidotti (2014)40 São  Luis,  MA  105  women  with  genital
lesions  clinically
suspected  for  HPV
infection
2011--2012  Brushing  Mouth
Populational studies
Castro  (2009)41 Maceió,  AL  30  women  with  genital
HPV  infection
2005--2006  Brushing  Mouth
Xavier (2009)42 São  Paulo,  SP  30  men  with  anogenital
HPV  infection
2009  Brushing  and  fresh
tissue
Mouth
Peixoto (2011)43 Salvador,  BA  100  women  with  genital
lesions  conﬁrmed  for
HPV infection
2011  Brushing  Mouth
Zonta (2012)44 São  Paulo,  SP  27  women  from  prison
with  pre-malignant  or
malignant  lesions  of  the
uterine  cervix
2012  Brushing  Mouth
Oral/oropharyngeal  HPV  infection  in  immunodeﬁcient  patients  (all  comparative  studies  with  healthy  patients)
Araujo (2011)45 Curitiba,  PR  60  patients  with
Fanconi’s  anemia  and
severe  anaplastic  anemia
and  16  healthy  control
2011  Brushing  Mouth
Lima (2014)46 São  Paulo,  SP  100  women  with  HIV  and
100  healthy  women
2013  Brushing  Mouth
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Brasília / Distrito Federal:
Marques 2013, Cantarutti 2014
Goiânia / Goiás:
Spindula-Filho 2011,
Cordeiro-Silva 2012, Lopez 2014
Campo Grande / Mato Grosso do Sul:
Machado 2014
Votuporanga / São Paulo: Cavenaghi 2013
São José do Rio Preto / São Paulo:
Cortezzi 2004, Sacramento 2006
Araçatuba / São Paulo: Simonato 2008
Araraquara / São Paulo:
Miguel 1998, Soares 2002, Soares 2003,
Fregonesi 2003, Mazon 2011
Curitiba / Paraná:
Araújo 2011
Belém / Pará: Araújo 2014
São Luis / Maranhão: Vidotti 2014
Natal / Rio Grande do Norte:
Soares 2007, Soares 2008,
Oliveira 2009, Pereira 2011
Recife / Pernambuco:
   Ribeiro 2014
Maceió / Alagoas: Castro 2009
Salvador / Bahia: Peixoto 2011
Montes Claros / Minas Gerais:
  Marques-Silva 2012, Fonseca-Silva 2012
Vitória / Espirito Santo: Cordeiro-Silva 2012
Araras / São Paulo: Betiol 2012, Tristão  2012
Campinas / São Paulo: Gonçalves 2006, Horewicz 2010
São Paulo / São Paulo:
Miguel 1998, Cortezzi 2004, Silva 2007, Acay 2008, Xavier 2009,
Zonta 2012, Kaminagakura 2012, Kreimer 2013, Lima 2014, Lopez 2014
Rio de Janeiro / Rio de Janeiro:
  Esquenazi 2010, Lopez 2014
Ribeirão Preto / São Paulo:
  Oliveira 2008, Lira 2010, Fregonezi 2012, Lopez 2014
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iFigure  2  Article  distribution  a
established  a  similar  rate  of  27.4%  for  HPV  infections  in
patients  with  SCC  of  the  oral  cavity  or  oropharynx  and  of
8.0%  speciﬁcally  for  HPV  16  infection.  For  HPV  18  infection,
a  rate  of  23.7%  was  observed  among  SCC  patients  in  the
present  review,  possibly  the  ﬁrst  report  in  this  ﬁeld  with
a  large  sample.  Other  series,55 however,  reported  an  unex-
pected  extreme  rarity  of  HPV  18  in  the  oropharynx  that  was
conﬁrmed  in  other  large  studies,  and  the  authors  discussed
how  this  was  a  difﬁcult  fact  to  explain.
O’Rorke  et  al.57 performed  a  meta-analysis  with  42
articles  studying  the  survival  rate  of  HNSCC  patients.
They  concluded  that  patients  with  HPV-positive  HNSCC
had  a  54%  better  overall  survival  rate  compared  to  HPV-
negative  patients  (HR  0.46,  95%  CI  0.37--0.57)  and  that  both
progression-free  survival  and  disease-free  survival  were  sig-
niﬁcantly  improved  in  HPV-positive  HNSCCs.  This  was  not  the
aim  of  the  present  review,  but  it  demonstrates  the  current
relevance  of  the  study  of  this  topic.
Demographics
Demographically,  patients  with  HPV-related  HNSCCs  are
more  likely  to  be  male,  white,  non-smokers,  non-drinkers,
younger  in  age,  and  have  a  higher  socioeconomic  status.57--60
Changes  in  sexual  behavior,  including  a  higher  number  of
lifetime  sex  partners,  an  increase  in  oral  sex  practices,
same  sex-contact,  and  earlier  age  of  sexual  activity  have
all  been  implicated  in  HPV-related  HNSCC.57,61 Many  of  the
studies  included  in  this  review  did  not  present  ﬁndings  by
potentially  important  covariates  (age,  gender,  tobacco  use,
alcohol  use,  etc.), as  was  observed  in  other  studies.55,62
Moreover,  only  eight  studies  (38.1%)  employed  a  cancer-free
control  group,  which  is  difﬁcult  and  can  sometimes  cause  an
t
o
t
1ding  to  Brazilian  city  and  state.
verestimation  of  the  odds  ratio  of  HPV  risk  infection
etween  HNSCC  groups.  The  same  trend  was  observed  by
errero  et  al.62
The  variations  in  oral  HPV  prevalence  among  different
tudies  may  be  due  to  differences  in  study  populations,
ampling  and  testing  methods,  and  possibly  the  time  periods
tudied.47
ample  analysis
n  the  absence  of  a  standardized  detection  technique,  con-
iderable  variations  in  the  prevalence  of  HPV  infections  have
een  recorded  in  the  literature.54 This  was  not  observed  in
he  present  review  because  the  great  majority  of  the  studies
mployed  GP  5+/6+  or  MY09/11  primers  in  polymerase  chain
eaction  (PCR)  or  HPV  type-speciﬁc  in  situ  hybridization.
eographic  distribution
he  prevalence  of  HPV  was  assessed  in  a study  with  1688
ealthy  men  (median  age  of  31  years)  in  the  U.S.,  Mexico,
nd  Brazil.  The  prevalence  of  all  HPV  types  was  4.0%  (95%
I  3.1%--5.0%).10 The  most  prevalent  high-risk  HPV  type  was
PV  16  in  all  three  countries;  however,  HPV55  was  more
ommon  in  Mexico  compared  to  the  U.S.  or  Brazil.  The  geo-
raphic  heterogeneity  might  be  partly  explained  by  regional
ifferences  in  the  distribution  of  risk  factors  other  than  HPV
nfection  in  HNSCC  patients.55
The  study  by  Gillison  et  al.48 estimated  an  HPV  infec-
ion  rate  of  6.9%  in  the  general  U.S.  population  in  a  sample
btained  in  2009  and  2010.  This  rate  was  slightly  higher  than
hat  observed  in  a  systematic  review  that  included  data  from
997  to  2009  (4.5%;  95%  CI  3.9--5.1).63
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Table  2  Clinical  characteristics  of  patients  of  the  included  studies  (when  obtained  from  original  article).
Article  Age  Smoking  status  (%)  Alcohol  intake  (%)  Men/women
Oral/oropharyngeal  HPV  infection  in  healthy  patients
Sacramento  (2006)6 Mean  of  25  y  14.3%  71.4%  21/29
Esquenazi (2010)7 Mean  of  23  y  3.0%  3.0%  40/60
Horewicz (2010)8 Mean  of  38  y  3.8%  --  28/76
Tristão (2012)9 Predominantly  between  18  and  21
y
--  --  37/88
Kreimer (2013)10 47%  under  30  y
83%  under  44  y
40.0%  74.0%  499/0
Cavenaghi (2013)5 Mean  of  51  y  75.0%  37.1%  77/47
Araujo (2014)11 Mean  of  36  y  6.6%  23.5%  63/103
Machado (2014)12 Mean  of  23  y  --  --  0/514
Weighted average  30  years  318/1043  (30.5%)  493/939  (52.5%)  --
Oral/oropharyngeal  HPV  infection  in  patients  with  benign  or  premalignant  lesions
Fonseca-Silva  (2012)14 Means:  32  y  (control);  54  y
(dysplasia)
56.9%  61.1%  39/33
HPV infection  in  oral  cavity  and/or  oropharyngeal  squamous  cell  carcinoma  patients
Comparative  studies  (healthy  people  versus  SCC  patients)
Cortezzi  (2004)15 Mean  of  61  y  --  --  106/52
Silva (2007)16 Over  40  y  100.0%  --  --
Comparative studies  (benign  lesions  versus  SCC  patients)
Lira (2010)22 Mean  of  57  y  80.2%  66.3%  71/15
Population studies
Miguel  (1998)24 Mean  of  61  y  90.5%  --  42/3
Soares (2007)25 Mean  of  65  y  --  --  49/26
Oliveira (2008)26 Mean  of  59  y  81.6%  --  73/14
Simonato (2008)27 79.3%  under  60  y  89.7%  62.1%  27/2
Soares (2008)28 Mean  of  65  y  --  --  --
Oliveira (2009)29 59%  over  60  y  --  --  57/31
Pereira (2011)30 Mean  of  63  y  --  --  19/8
Spindula-Filho  (2011)31 55.3%  over  65  y  72.3%  61.7%  34/13
Cordeiro-Silva  (2012)32 44.5%  over  58  y  80.0%  68.9%  35/10
Kaminagakura  (2012)33 Mean  of  51  y  84.0%  62.0%  81/33
Marques-Silva (2012)34 33.3%  under  45  y  96.0%  93.3%  34/6
Cantarutti (2014)35 Mean  of  56  y  92.0%  65.0%  16/10
Lopez (2014)36 45%  under  55  y 93.7%  95.6%  --
Weighted average  59  years  703/801  (87.8%)  458/609  (75.2%)  --
Oral/oropharyngeal  HPV  infection  in  patients  with  genital  HPV  infection
Comparative  studies  (healthy  people  versus  patients  with  genital  HPV  infection)
Gonc¸alves (2006)37 Mean  of  30  y  29.3%  --  0/140
Marques (2013)38 Mean  of  45  y  --  --  21/43
Ribeiro (2014)39 Mean  of  32  y  27.4%  --  31/31
Vidotti (2014)40 41.9%  under  30  y  7.6%  33.3%  0/105
Population studies
Castro  (2009)41 Mean  of  28  y  30.0%  0.0%  0/30
Xavier (2009)42 Mean  of  29  y  --  --  30/0
Peixoto (2011)43 Mean  of  30  y  15.0%  88.1%  0/100
Zonta (2012)44 74.1%  under  35  y  66.7%  --  0/27
Weighted average  32  years  90/437  (20.6%)  123/235  (52.3%)  --
Oral/oropharyngeal  HPV  infection  in  immunodeﬁcient  patients  (all  comparative  studies  with  healthy  people)
Lima (2014)46 Mean  of  36  y  31.0%  50.0%  0/200
Weighted average  36  years  62/200  (31.0%)  100/200  (50.0%)  --
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Table  3  HPV  status  in  each  subgroup.
Article  Total HPV+  HPV  16 HPV  18 HPV  16/18
Oral/oropharyngeal  HPV  infection  in  healthy  patients
Cortezzi  (2004)15 142  15  (10.6%) 13  (9.1%) -- 13  (9.1%)
Gonc¸alves (2006)37 70  3  (4.3%) -- -- --
Sacramento  (2006)6 50  7  (14.0%) 1  (2.0%) 1  (2.0%) 2  (4.0%)
Silva (2007)16 10  1  (10.0%) -- -- --
Esquenazi  (2010)7 100  0  (0.0%) -- -- --
Horewicz  (2010)8 104  0  (0.0%) 0  (0.0%) -- --
Araujo (2011)45 16  1  (6.2%) 0  (0.0%) 0  (0.0%) 0  (0.0%)
Betiol (2012)13 16  3  (18.8%) 0  (0.0%) 3  (18.8%) 3  (18.8%)
Fonseca-Silva (2012)14 24  7  (29.2%) 5  (20.8%) 2  (8.3%) 7  (29.2%)
Tristão (2012)9 125  29  (23.2%) -- -- --
Kreimer  (2013)10 499  10  (2.0%) 3  (0.6%) 0  (0.0%) 3  (0.6%)
Cavenaghi (2013)5 124  3  (2.4%) -- -- --
Araujo  (2014)11 166  40  (24.1%) 0  (0.0%) 5  (3.0%) 5  (3.0%)
Lima (2014)46 100  2  (2.0%) -- -- --
Machado  (2014)12 514  7  (1.3%)  0  (0.0%)  0  (0.0%)  0  (0.0%)
Total 2060  128/2060  (6.2%)
(95%  CI  5.7%--6.7%)
22/1551  (1.4%)
(95%  CI  1.2%--1.6%)
11/1285  (0.9%)
(95%  CI  0.8%--1.0%)
33/1551  (2.1%)
(95%  CI  1.9%--2.3%)
Oral/oropharyngeal  HPV  infection  in  patients  with  benign  lesions
Soares  (2003)19 30  6  (20.0%) -- -- 2  (6.7%)
Fregonesi (2003) 19  6  (31.6%) -- -- 4  (21.0%)
Lira (2010)22 16  16  (100.0%) -- -- --
Mazon  (2011)17 18  6  (33.0%) 0  (0.0%) 0  (0.0%) 0  (0.0%)
Fregonezi (2012)23 18  11  (61.1%) 0  (0.0%) 7  (39.0%) 7  (39.0%)
Total 101 45/101  (44.6%)
(95%  CI  43.7--45.4)
0/36  (0.0%)
(95%  CI  NA)
7/36  (19.4%)
(95%  CI  17.8--21.1)
13/85  (15.3%)
(95%  CI  14.7--15.9)
Oral/oropharyngeal  HPV  infection  in  patients  with  premalignant  lesions
Soares (2002)18 20  2  (10.0%) --  --  --
Fregonesi (2003)20 10  6  (60.0%)  --  --  4  (40.0%)
Acay (2008) 40  9  (22.5%) --  --  5  (12.5%)
Mazon (2011)17 18  4  (22.0%)  0  (0.0%)  4  (22.0%)  4  (22.0%)
Betiol (2012)13 8  8  (100.0%)  0  (0.0%)  5  (62.5%)  5  (62.5%)
Fonseca-Silva (2012)14 48  34  (70.8%)  31  (64.6%)  3  (6.2%)  34  (70.8%)
Fregonezi (2012)23 16  8  (50.0%)  0  (0.0%)  4  (25.0%)  4  (25.0%)
Total 160  71/160  (44.4%)
(95%  CI  42.7%--46.1%)
31/90  (34.4%)
(95%  CI  31.2%--37.7%)
16/90  (17.8%)
(95%  CI  17.6%--38.6%)
51/140  (36.4%)
(95%  CI  34.4%--38.6%)
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Table  3  (Continuación  )
Article Total HPV+ HPV 16 HPV 18 HPV 16/18
Oral/oropharyngeal HPV infection in patients with oral or oropharyngeal SCC
Miguel (1998)24 28 4 (14.3%) -- -- --
Soares  (2002)18 10 0 (0.0%) -- -- --
Soares  (2003)19 27 13 (48.1%) -- -- 10 (37.0%)
Fregonesi (2003)20 17 6 (35.3%) -- -- 5  (29.0%)
Cortezzi  (2004)15 16 4 (25.0%) 4 (25.0%) -- --
Silva  (2007)16 50 37 (74.0%) -- -- --
Soares  (2007)25 75 18 (24.0%) 1 (1.3%) 14 (18.7%) 15 (20.0%)
Acay (2008)21 10 3 (30.0%) -- -- 2  (20.0%)
Oliveira  (2008)26 87 17 (19.5%) 4 (4.6%) 3 (3.4%) 7  (8.0%)
Simonato  (2008)27 29 5 (17.2%) -- -- --
Soares  (2008)28 33 11 (33.3%) 2 (6.1%) 9 (27.3%) 11 (33.3%)
Oliveira (2009)29 88 26 (29.5%) 1 (3.8%) 21 (80.8%) 22 (25.0%)
Lira (2010)22 70 63 (90.0%) 11 (13.9%) 17 (21.5%) 28 (40.0%)
Mazon (2011)17 19 11 (58.0%) 1 (5.3%) 10 (53.0%) 11 (58.0%)
Pereira (2011)30 27 9 (33.3%) 1 (3.7%) 9 (33.3%) 9  (33.3%)
Spindula-Filho (2011)31 47 0 (0.0%) -- -- --
Cordeiro-Silva (2012)32 45 3 (6.0%) -- -- --
Fregonezi  (2012)23 17 5 (29.4%) 0 (0.0%) 2 (11.8%) 2  (11.8%)
Kaminagakura (2012)33 114 22 (19.2%) 22 (19.2%) -- 22 (19.2%)
Marques-Silva (2012)34 40 30 (75.0%) 10 (25.0%) 23 (57.5%) 30 (75.0%)
Cantarutti (2014)35 26 0 (0.0%) -- -- --
Lopez  (2014)36 222 14 (6.3%) 8 (3.6%) -- 8  (3.6%)
Total 1097 301/1097 (27.4%)
(95% CI 26.6%--28.3%)
65/808 (8.0%)
(95% CI 7.6%--8.5%)
108/456 (23.7%)
(95% CI 23.0%--24.4%)
182/846 (21.5%)
(95% CI 20.9%--22.1%)
Oral/oropharyngeal HPV infection in patients with genital lesions, HPV infection, or partners of this population.
Gonc¸alves, 200637 70 26 (37.1%) -- -- --
Castro,  200941 30 0 (0.0%) -- -- --
Xavier,  200942 30 1 (3.3%) -- -- --
Peixoto,  201143 100 81 (81.0%) -- -- --
Zonta,  201244 27 23 (85.2%) 2 (7.4%) 1 (3.7%) 3  (11.1%)
Marques,  201338 64 2 (3.1%) -- -- --
Ribeiro,  201439 62 30 (48.4%) -- -- --
Vidotti,  201440 105 25 (23.8%) -- -- --
Total  488 188/488 (38.5%)
(95% CI 36.2%--40.9%)
2/23 (7.4%)
(95% CI NA)
1/23 (3.7%)
(95% CI NA)
3/23 (11.1%)
(95% CI NA)
Oral/oropharyngeal HPV infection in immunodeﬁcient patients
Araujo, 201145 60 20 (33.3%) 8 (13.3%) 2 (3.3%) 10 (16.7%)
Lima, 201446 100 11 (11.0%) -- -- --
Total  160 31/160 (19.4%)
(95% CI 18.4%--20.4%)
8/60 (13.3%)
(95% CI NA)
2/60 (3.3%)
(95% CI NA)
10/60 (16.7%)
(95% CI NA)
Oral  HPV  prevalence  in  Brazilian  population  studies  
Table  4  Risk  of  HPV  infection  in  each  subgroup.
Group  OR  (95%  CI)  pa
Any  HPV  infection
Healthy  patients  Reference  --
Immunodeﬁcient
patients
5.797  (3.696--9.091)  <0.0001
Risk group  3.888  (3.369--4.487)  <0.0001
Benign lesions  2.686  (2.312--3.121)  <0.0001
Premalignant  lesions  2.094  (1.904--2.304)  <0.0001
Oral or  oropharyngeal
SCC
3.097  (2.700--3.553)  <0.0001
HPV 16  infection
Healthy  patients Reference --
Immunodeﬁcient
patients
9.400  (4.021--21.977)  <0.0001
Risk group 2.476  (1.167--5.255)  0.018
Benign lesions N/C  --
Premalignant  lesions 2.467  (2.121--2.870)  <0.0001
Oral or  oropharyngeal
SCC
1.725  (1.180--1.522) 0.005
HPV 18  infection
Healthy  patients  Reference  --
Immunodeﬁcient
patients
3.894  (0.844--17.960)  0.081
Risk group  2.254  (0.793--6.402)  0.127
Benign lesions  3.044  (2.169--4.271)  <0.0001
Premalignant  lesions  2.242  (1.839--2.740)  <0.0001
Oral or  oropharyngeal
SCC
2.051  (1.807--2.327)  <0.0001
HPV 16/18  infection
Healthy  patients  Reference  --
Immunodeﬁcient
patients
7.833  (3.689--16.633)  <0.0001
Risk group  2.476  (1.324--4.629)  0.005
Benign lesions  2.040  (1.624--2.562)  <0.0001
Premalignant  lesions  2.278  (2.017--2.573)  <0.0001
Oral or  oropharyngeal
SCC
1.477  (1.043--2.092)  0.028
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RN/C, not calculated because there was no valid case for analysis.
a Logistic regression.
These  results  suggest  that  the  prevalence  of  HPV  may
vary  depending  on  distinct  population  characteristics  and
the  time  period  studied,  which  might  explain  the  wide  range
of  HPV  prevalence  among  different  studies  included  in  this
systematic  review.
Limitations
There  are  a  few  limitations  in  this  study  that  should  be
noted.  The  most  important  was  in  the  data  collection;
because  this  work  was  a  systematic  review  of  published  arti-
cles,  some  data  could  not  be  obtained,  especially  regarding
demographics.  Additionally,  as  seen  in  Fig.  2,  the  whole
Brazilian  population  was  not  included,  because  of  the  lack
of  studies  in  some  regions.  Another  important  point  is  that
because  aggregate  patient  data  were  used,  it  is  possible  that
there  was  heterogeneity  in  these  studies  and  inconsistencies565
n  the  datasets  that  were  unknown  due  to  the  summariza-
ion  of  the  data.  Moreover,  the  majority  of  the  studies  were
mall  and  used  nonprobability  samples,  and  it  is  difﬁcult
o  differentiate  studies  that  enrolled  consecutive  patients
rom  studies  that  used  alternative  inclusion  criteria,  such  as
nstitutional  archives  of  parafﬁn-embedded  tissues.  Never-
heless,  these  nonprobability  samples  did  not  represent  the
razilian  population  as  a  whole;  however,  the  present  study
s  the  ﬁrst  one  to  consolidate  the  data  of  oral  and  oropharyn-
eal  HPV  infection  in  Brazil.  HPV  prevalence  appeared  to
e  inversely  proportional  to  the  study  sample  size,  and  the
oor  quality  of  some  of  the  cancer  specimens  may  also  have
ffected  the  prevalence  estimates.  All  of  these  points  were
lso  mentioned  as  limitations  in  other  systematic  review
eries.55
onclusion
n  summary,  the  healthy  Brazilian  population  has  a  very
ow  oral/oropharyngeal  HPV  infection  rate.  Other  groups,
uch  as  at-risk  patients  or  their  partners,  immunodeﬁcient
atients,  people  with  oral  lesions  and,  especially,  patients
ith  oral  cavity  or  oropharyngeal  SCC,  have  high  risks  of  HPV
nfection.  Because  aggregate  patient  data  results  varied,  a
arge-scale  study  considering  the  whole  country,  including  a
ore  diverse  population,  must  be  conducted  to  conﬁrm  the
ndings  of  this  review.
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